Variation in SOFA (Sequential Organ Failure Assessment) Score Performance in Different Infectious States.
area under curve
clinical decision-making
critical care
mortality
organ dysfunction scores
sepsis
Journal
Journal of intensive care medicine
ISSN: 1525-1489
Titre abrégé: J Intensive Care Med
Pays: United States
ID NLM: 8610344
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
pubmed:
18
8
2020
medline:
18
9
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
In this study, we investigated whether the Sequential Organ Failure Assessment (SOFA) score performance differs based on the type of infection among patients admitted to the intensive care unit (ICU) with infection. Single-center, retrospective study of adult ICU patients admitted with infection between January 2008 and April 2018 at an urban tertiary care center. Patients were uniquely classified into different infection types based on International Classification of Diseases, Ninth Revision ( A total of 12 283 patients were included. Of these, 50.6% were female and the median age was 70 years (interquartile range: 57-82). The most common infection types were pneumonia (32.2%) and UTI (31.0%). Overall, 1703 (13.9%) patients died prior to hospital discharge. The median baseline SOFA score (within 24 hours of ICU admission) for the cohort was 5 (3-8). Patients with peritonitis had the highest median SOFA score, 7 (4-9), and patients with cellulitis and UTI had the lowest median SOFA score, 4 (2-7). The SOFA score discrimination to predict mortality was highest among patients with endocarditis (area under the receiver operating characteristic [AUC]: 0.79, 95% CI: 0.69-0.90) and lowest for patients with isolated bacteremia (AUC: 0.59, 95% CI: 0.49-0.70). Observed mortality by quartile of SOFA score differed substantially across infection types. Type of infection is an important consideration when interpreting the SOFA score. This is relevant as SOFA emerges as an important tool in the definition and prognostication of sepsis.
Identifiants
pubmed: 32799718
doi: 10.1177/0885066620944879
pmc: PMC7941324
mid: NIHMS1669715
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1217-1222Subventions
Organisme : NIGMS NIH HHS
ID : K23 GM128005
Pays : United States
Références
JAMA. 2017 Jan 17;317(3):290-300
pubmed: 28114553
Med Care. 2014 Jun;52(6):e39-43
pubmed: 23001437
Intensive Care Med. 2013 Jul;39(7):1253-61
pubmed: 23604133
Crit Care Med. 1981 Aug;9(8):591-7
pubmed: 7261642
J Infect Chemother. 2018 Mar;24(3):228-231
pubmed: 29258809
BMJ Open. 2015 Jan 06;5(1):e006616
pubmed: 25564146
Intern Med. 2017;56(14):1807-1815
pubmed: 28717075
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Crit Care Med. 2004 Jul;32(7):1510-26
pubmed: 15241096
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
BMC Infect Dis. 2018 Oct 26;18(1):535
pubmed: 30367601
Am J Emerg Med. 2016 Sep;34(9):1788-93
pubmed: 27321936
Chest. 1992 Jun;101(6):1644-55
pubmed: 1303622
Crit Care Med. 2011 Aug;39(8):1886-95
pubmed: 21516036
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Intensive Care Med. 1999 Jul;25(7):686-96
pubmed: 10470572
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
JAMA. 2016 Feb 23;315(8):762-74
pubmed: 26903335
JAMA. 2001 Oct 10;286(14):1754-8
pubmed: 11594901
Crit Care Med. 2009 Apr;37(4):1317-21
pubmed: 19242333
Antimicrob Agents Chemother. 2013 Aug;57(8):3969-75
pubmed: 23733476